VRDN

Viridian Therapeutics, Inc.

18.48 USD
-0.04 (-0.22%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Viridian Therapeutics, Inc. stock is down -2.43% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 7 February’s closed higher than January. In the last 3 Unusual Options Trades, there were 1 CALL, 2 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 Jan 14:33 19 Jul, 2024 20.00 CALL 37 83
21 Feb 15:06 20 Sep, 2024 20.00 PUT 212 96
21 Feb 15:06 20 Sep, 2024 20.00 PUT 195 96

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED) The company was founded in 2006 and is headquartered in Waltham, Massachusetts.